Andrea Ribeiro Soares

Andrea Ribeiro Soares

Auto-generated profile, based on publicly available information

Andrea Ribeiro Soares

Medical Sciences Faculty, Rio de Janeiro State University, Av 28 de setembro, 77, Vila Isabel, Rio de Janeiro, RJ, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2011 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
ASAndrea Soares
Andrea Soares
IBIrene Biasoli
Irene Biasoli
ASAdriana Scheliga
Adriana Scheliga
RBRenata Lyrio Baptista
Renata Lyrio Baptista
EBEloá Pereira Brabo
Eloá Pereira Brabo
NSNelson Spector
Nelson Spector

17 April 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
JMJuliana Mendonca
Juliana Mendonca
CCCláudia Dos Santos Cople-Rodrigues
Cláudia Dos Santos Cople-Rodrigues
JCJessyca Dias Do Amaral Cardoso
Jessyca Dias Do Amaral Cardoso
ASAndrea Ribeiro Soares
Andrea Ribeiro Soares
MFMarcos Kneip Fleury
Marcos Kneip Fleury
MCMarta Citelli
Marta Citelli
Dietary iron requirements in patients with sickle cell disease (SCD) remain unclear. SCD is a neglected hemoglobinopathy characterized by intense erythropoietic activity and anemia. Hepcidin is the hormone mainly responsible for iron homeostasis and intestinal absorption. Intense erythropoietic activity and anemia may reduce hepcidin transcription. By contrast, iron overload and inflammation may induce it. Studies on SCD have not evaluated the role of hepcidin in the presence and absence of iron overload. We aimed to compare serum hepcidin concentrations among individuals with sickle cell anemia, with or without iron overload, and those without the disease. Markers of iron metabolism and erythropoietic activity such as hepcidin, ferritin, and growth differentiation factor 15 were evaluated. Three groups participated in the study: the control group, comprised of individuals without SCD (C); those with the disease but without iron overload (SCDw); and those with the disease and iron overload (SCDio). Results showed that hepcidin concentration was higher in the SCDio > C > SCDw group. These data suggest that the dietary iron intake of the SCDio group should not be reduced as higher hepcidin concentrations may reduce the intestinal absorption of iron.

13 September 2014 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
SSSimone Lima de Souza
Simone Lima de Souza
FSFábio Santiago
Fábio Santiago
MRMarilza de Moura Ribeiro-Carvalho
Marilza de Moura Ribeiro-Carvalho
AAAdriano Arnóbio
Adriano Arnóbio
ASAndréa Ribeiro Soares
Andréa Ribeiro Soares
MOMaria Helena Ornellas
Maria Helena Ornellas
Central nervous system involvement is considered a rare complication of chronic lymphocytic leukemia, and so there is the risk of being overlooked. We report a case of central nervous system involvement in a 75-year-old mulatto woman with chronic lymphocytic leukemia after 5 years of follow-up and a literature review on the subject. The clinical course, treatment and outcome are described. A systematic, meticulous and comprehensive analysis of existing publications regarding chronic lymphocytic leukemia with central nervous system involvement was performed. We concluded that central nervous system involvement of chronic lymphocytic leukemia is probably not associated with any evident risk factors. Diagnostic approach differs by institutions but often includes imaging, morphology and flow cytometry. Resolution of central nervous system symptoms can usually be accomplished with intrathecal chemotherapy or irradiation followed by systemic treatment. The recognition of this entity by clinicians could lead to early detection and treatment, resulting in better outcomes in this rare complication.

1 January 2021 in Hematology
Verified
Journal Article
Open access
CACarlos Henrique Stohler de Almeida
Carlos Henrique Stohler de Almeida
LRLuis Felipe Fonseca Reis
Luis Felipe Fonseca Reis
LNLeila Paula Alves da Silva Nascimento
Leila Paula Alves da Silva Nascimento
ASAndrea Ribeiro Soares
Andrea Ribeiro Soares
MMMaria Christina Paixão Maioli
Maria Christina Paixão Maioli
Agnaldo José LopesAgnaldo José Lopes
Agnaldo José Lopes
Considering the advances in functional rehabilitation in recent decades, therapist-oriented home rehabilitation (TOHR) has been increasingly used in the field of physical therapy because it increas...

1 March 2020 in International Journal of Cardiology
Verified
Journal Article
Closed access
ASAndrea Soares
Andrea Soares
DBDavid L. Brown
David L. Brown

21 February 2017 in Hematology
Verified
Journal Article
Closed access
ROBERIA DE PONTESROBERIA DE PONTES
ROBERIA DE PONTES
ECElaine Sobral da Costa
Elaine Sobral da Costa
PSPatricia Fernanda Rosa de Siqueira
Patricia Fernanda Rosa de Siqueira
JMJussara F. F. Medeiros
Jussara F. F. Medeiros
ASAndréa Soares
Andréa Soares
MFMarcos K. Fleury
Marcos K. Fleury
Objectives: Cholecystitis is one of the complications of symptomatic cholelithiasis responsible for high levels of morbidity of sickle cell disease (SCD) patients. Here, we investigated the possible protective role of single gene deletions of α-thalassaemia in the occurrence of cholelithiasis and cholecystitis in SCD patients, as well as the cholecystectomy requirements. Methods: The α-globin genotype was determined in 83 SCD patients using the multiplex-polymerase chain reaction and compared with clinical events. Results: Overall, in 23% of patients, -α3.7 deletion was found. α-Thalassaemia concomitant to SCD was an independent protective factor to cholecystitis (OR = 0.07; 95% CI: 0.01–0.66; p = 0.020) and cholecystectomy requirement (OR = 0.14; 95% CI: 0.03–0.60; p = 0.008). The risk of cholelithiasis was not affected by the α-thalassaemia concomitance. Conclusions: To the best our knowledge, our study is the first to show the protective effect of α-thalassaemia on cholecystitis and cholecystectomy requirements in SCD, which may be due to an improved splenic function.